ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,759Medicare Part D Prescriptions Filled, Including Refills

Rank: 568 out of 4623

$578K Total Retail Price of All Prescriptions

Rank: 552 out of 4623

942 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
68% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

6% of this provider’s 942 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

3% of this provider’s 8,177 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

10 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
LISINOPRIL 551 492 1 4
SIMVASTATIN 475 418 2 2
METFORMIN HCL 349 282 3 6
LEVOTHYROXINE SODIUM 330 298 4 1
ALENDRONATE SODIUM 326 296 5 22
OMEPRAZOLE 324 260 6 7
GEMFIBROZIL 280 239 7 94
MELOXICAM 236 171 8 27
AMLODIPINE BESYLATE 185 148 9 5
METOPROLOL SUCCINATE 159 141 10 13
HYDROCHLOROTHIAZIDE 158 135 11 10
GLIMEPIRIDE 156 112 12 38
LOSARTAN POTASSIUM 136 119 13 21
GABAPENTIN 133 107 14 16
NABUMETONE 124 100 15 188
PANTOPRAZOLE SODIUM 123 106 16 35
METOPROLOL TARTRATE 112 92 17 9
TRAMADOL HCL 112 103 17 15
ZOLPIDEM TARTRATE 108 87 19 18
ATENOLOL 104 83 20 28
FAMOTIDINE 102 95 21 82
GLYBURIDE 102 78 R 21 59
LOSARTAN-HYDROCHLOROTHIAZIDE 100 94 23 46
NAMENDA 98 94 24 36
FINASTERIDE 94 87 25 109
HYDROCODONE-ACETAMINOPHEN 94 52 S3 25 3
IBUPROFEN 92 50 27 65
GLYBURIDE-METFORMIN HCL 89 84 R 28 56
CLOPIDOGREL 88 85 29 31
TAMSULOSIN HCL 88 83 29 29
WELCHOL 87 56 31 276
GLIPIZIDE 87 67 31 49
MECLIZINE HCL 86 75 33 125
ATORVASTATIN CALCIUM 80 74 34 12
SERTRALINE HCL 79 63 35 26
CILOSTAZOL 79 75 35 176
LISINOPRIL-HYDROCHLOROTHIAZIDE 74 70 37 19
NEXIUM 73 58 38 17
PLAVIX 73 68 38 45
LOVAZA 70 49 40 112
LANTUS 69 56 41 44
ZETIA 69 60 41 92
JANUVIA 67 42 43 52
WARFARIN SODIUM 65 62 44 24
BUSPIRONE HCL 65 51 44 135
CEFADROXIL 63 54 46 320
FUROSEMIDE 59 57 47 8
NAPROXEN 56 42 48 63
VYTORIN 55 38 49 170
CARVEDILOL 55 51 49 25
NITROFURANTOIN MONO-MACRO 54 40 51 172
PENTOXIFYLLINE 53 45 52 245
GLIPIZIDE ER 52 46 53 86
LYRICA 50 31 54 66
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 12, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.